61166-04-9

Basic information

• Product Name: 9-Methyl-3-aminocarbazole
• Synonyms: 3-Amino-9-methyl-9H-carbazole;3-Amino-9-methylcarbazole;9-Methyl-3-aminocarbazole;9-Methylcarbazol-3-amine;9-methyl-9H-carbazol-3-amine
• CAS NO: 61166-04-9
• Molecular Formula: C₁₃H₁₂N₂
• Molecular Weight: 196.24778
• Mol File: 61166-04-9.mol
• Article Data: 13

Chemical Properties

• Melting Point: 174 °C
• Boiling Point: 415.4°Cat760mmHg
• Flash Point: 205°C
• Appearance: /
• Density: 1.2g/cm³
• Vapor Pressure: 4.13E-07mmHg at 25°C
• Refractive Index: 1.664
• PKA: 4.99±0.30(Predicted)
• CAS DataBase Reference: 9-Methyl-3-aminocarbazole(CAS DataBase Reference)
• NIST Chemistry Reference: 9-Methyl-3-aminocarbazole(61166-04-9)
• EPA Substance Registry System: 9-Methyl-3-aminocarbazole(61166-04-9)

Safety Data

• Hazardous Substances Data: 61166-04-9(Hazardous Substances Data)

Usage

InChI:InChI=1/C13H12N2/c1-15-12-5-3-2-4-10(12)11-8-9(14)6-7-13(11)15/h2-8H,14H2,1H3

Upstream product

• 61166-05-0 9-methyl-3-nitro-9H-carbazole 
• 17754-68-6 N,N'-dimethyl-N,N'-diphenyl-1,4-phenylenediamine 
• 1484-12-4 N-methylcarbazole 
• 86-74-8 9H-carbazole 
• 3077-85-8 3-Nitro-carbazol 

Downstream Products

• 180331-84-4 N-(9-methyl-carbazol-3-yl)-acetamide 
• 65213-19-6 o-Hydroxyphenyl-N-(3-N-methylcarbazolyl)azomethine 
• 56525-80-5 N,N'-Dimethyl-5,11-dihydroindolo<3,2-b>carbazol 
• 180331-85-5 (9-Methyl-9H-carbazol-3-yl)-phenyl-amine 
• 86885-08-7 9-methyl-3-(N-methylanilino)carbazole 
• 5416-98-8 3-(N-methylamino)-9-methylcarbazole 
• 94127-15-8 3-(N,N-dimethylamino)-9-methylcarbazole 
• 1234193-61-3 7-methyl-1,3-diphenyl-7H-pyrido[2,3-c]carbazole 
• 1353648-61-9 ethyl 4-(9-methyl-9H-carbazol-3-ylamino)-2-(4-nitrophenyl)-5-oxo-2,5-dihydro-3-furancarboxylate 

Relevant articles and documents

Carbazole-decorated fluorescent CdS quantum dots: A potential light-harvesting material

An organic-inorganic nanohybrid system (AMC-CdS QD) comprised of a fluorescent carbazole analog, AMC (3-amino-N-methyl carbazole), and CdS QDs has been synthesized, which shows promise as a sustainable energy harvesting material. FT-IR and 1H NMR spectroscopy have ascertained the covalent grafting of the carbazole moieties onto the mercaptopropionic acid (MPA)-capped surface of the CdS QDs. Detailed photophysical characterization of this nanohybrid system have confirmed the occurrence of efficient F?rster resonance energy transfer (FRET) from its organic to inorganic counterpart. This phenomenon was also demonstrated using SCC-DFTB-based quantum chemical calculations. As explored in the present work, the photoelectron transfer efficiency of AMC-CdS QDs signifies their plausible future applications as light-harvesting materials.

Synthesis of Novel 3-N-substituted Carbazole Derivatives and Evaluation of their Abilities to Inhibit Platelet Aggregation

The carbazole moiety exhibits various biological activities, including anticancer, antiviral, anti-inflammatory, and antimicrobial activities; some compounds containing the moiety also inhibit platelet aggregation. In the present study, we synthesized a series of 3-N-substituted carbazole derivatives and evaluated their abilities to inhibit in vitro platelet aggregation induced by collagen (5 μg/mL). Of the synthesized compounds, compound 5q (JSCa15), with a urea linkage within the carbazole framework, exhibited the strongest inhibitory activity (98.25% at 30 μM). Interestingly, reduction of the nitro group of compound 5q to an amine exhibited significantly decreased activity (compound 5r, 5.18% at 30 μM). Also, substitution of the urea moiety of compound 5q with a carbamate moiety resulted in a considerable loss of activity (compound 8a, 5.91% at 30 μM). These results suggest that the urea moieties and nitro groups of 3-N-substituted carbazole derivatives may play key roles in inhibiting in vitro platelet aggregation induced by collagen.

1-CYANO-PYRROLIDINE DERIVATIVES AS INHIBITORS OF USP30.

The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylatingenzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C- terminal hydrolase 30 or Ubiquitin Specific Peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the invention include compounds having the formula (I) (I) or a pharmaceutically acceptable salt thereof, wherein R1, R 2, R 3, m, L and X are as defined herein.